CPMV-DOX Delivers

Alaa A. A. Aljabali; Sourabh Shukla; George P. Lomonossoff; Nicole F. Steinmetz; David J. Evans

doi:10.1021/mp3002057

CPMV-DOX Delivers

Alaa A. A. Aljabali, Sourabh Shukla, George P. Lomonossoff, Nicole F. Steinmetz, David J. Evans

School of Biological Sciences

Research output: Contribution to journal › Article › peer-review

134 Citations (Scopus)

Abstract

The plant virus, Cowpea mosaic virus (CPMV), is developed as a carrier of the chemotherapeutic drug doxorubicin (DOX). CPMV-DOX conjugate, in which eighty DOX molecules are covalently bound to external surface carboxylates of the viral nanoparticle (VNP), shows greater cytotoxicity than free DOX toward HeLa cells when administered at low dosage. At higher concentrations, CPMV-DOX cytotoxicity is time-delayed. The CPMV conjugate is targeted to the endolysosomal compartment of the cells, in which the proteinaceous drug carrier is degraded and the drug released. This study is the first demonstrating the utility of CPMV as a drug delivery vehicle.

Original language	English
Pages (from-to)	3-10
Number of pages	8
Journal	Molecular Pharmaceutics
Volume	10
Issue number	1
Early online date	24 Jul 2012
DOIs	https://doi.org/10.1021/mp3002057
Publication status	Published - 7 Jan 2013

Keywords

cancer
Cowpea mosaic virus
doxorubicin
drug delivery
viral nanoparticle

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/mp3002057

http://pubs.acs.org/doi/abs/10.1021/mp3002057

Cite this

@article{accd67a9542f476989e52a089f12559e,

title = "CPMV-DOX Delivers",

abstract = "The plant virus, Cowpea mosaic virus (CPMV), is developed as a carrier of the chemotherapeutic drug doxorubicin (DOX). CPMV-DOX conjugate, in which eighty DOX molecules are covalently bound to external surface carboxylates of the viral nanoparticle (VNP), shows greater cytotoxicity than free DOX toward HeLa cells when administered at low dosage. At higher concentrations, CPMV-DOX cytotoxicity is time-delayed. The CPMV conjugate is targeted to the endolysosomal compartment of the cells, in which the proteinaceous drug carrier is degraded and the drug released. This study is the first demonstrating the utility of CPMV as a drug delivery vehicle.",

keywords = "cancer, Cowpea mosaic virus, doxorubicin, drug delivery, viral nanoparticle",

author = "Aljabali, {Alaa A. A.} and Sourabh Shukla and Lomonossoff, {George P.} and Steinmetz, {Nicole F.} and Evans, {David J.}",

year = "2013",

month = jan,

day = "7",

doi = "10.1021/mp3002057",

language = "English",

volume = "10",

pages = "3--10",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

number = "1",

}

TY - JOUR

T1 - CPMV-DOX Delivers

AU - Aljabali, Alaa A. A.

AU - Shukla, Sourabh

AU - Lomonossoff, George P.

AU - Steinmetz, Nicole F.

AU - Evans, David J.

PY - 2013/1/7

Y1 - 2013/1/7

N2 - The plant virus, Cowpea mosaic virus (CPMV), is developed as a carrier of the chemotherapeutic drug doxorubicin (DOX). CPMV-DOX conjugate, in which eighty DOX molecules are covalently bound to external surface carboxylates of the viral nanoparticle (VNP), shows greater cytotoxicity than free DOX toward HeLa cells when administered at low dosage. At higher concentrations, CPMV-DOX cytotoxicity is time-delayed. The CPMV conjugate is targeted to the endolysosomal compartment of the cells, in which the proteinaceous drug carrier is degraded and the drug released. This study is the first demonstrating the utility of CPMV as a drug delivery vehicle.

AB - The plant virus, Cowpea mosaic virus (CPMV), is developed as a carrier of the chemotherapeutic drug doxorubicin (DOX). CPMV-DOX conjugate, in which eighty DOX molecules are covalently bound to external surface carboxylates of the viral nanoparticle (VNP), shows greater cytotoxicity than free DOX toward HeLa cells when administered at low dosage. At higher concentrations, CPMV-DOX cytotoxicity is time-delayed. The CPMV conjugate is targeted to the endolysosomal compartment of the cells, in which the proteinaceous drug carrier is degraded and the drug released. This study is the first demonstrating the utility of CPMV as a drug delivery vehicle.

KW - cancer

KW - Cowpea mosaic virus

KW - doxorubicin

KW - drug delivery

KW - viral nanoparticle

U2 - 10.1021/mp3002057

DO - 10.1021/mp3002057

M3 - Article

VL - 10

SP - 3

EP - 10

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -